A New Vasopressin V1a Antagonist Restores Social Behavior in the Mouse CNTNAP2KO Model of Autism

被引：0
|
作者：
Grundschober, Christophe [1 ]
Genet, Audrey [1 ]
Saxe, Michael [1 ]
Schnider, Patrick [1 ]
Biemans, Barbara [1 ]
机构：
[1] F Hoffmann La Roche Ltd, Basel, Switzerland
来源：
NEUROPSYCHOPHARMACOLOGY | 2017年 / 42卷
关键词：
Autism Spectrum Disorders; Vasopressin 1a Receptor Antagonist; Genetic Mouse Model; CNTNAP2;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
W42
引用
收藏
页码：S502 / S502
页数：1
相关论文
共 50 条
  • [21] In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat
    Risvanis, J
    Naitoh, M
    Johnston, CI
    Burrell, LM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 381 (01) : 23 - 30
  • [22] Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Phasic and Sustained Threat in Humans
    Lago, Tiffany
    Brownstein, Michael
    Beydler, Emily
    Manbeck, Adrienne
    Beale, Alexis
    Simon, Neal
    Grillon, Christian
    Ernst, Monique
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 394 - 394
  • [23] Impaired social interaction and reduced anxiety-related behavior in vasopressin V1a receptor knockout mice
    Egashira, Nobuaki
    Tanoue, Akito
    Matsuda, Tomomi
    Koushi, Emi
    Harada, Satoko
    Takano, Yukio
    Tsujimoto, Gozoh
    Mishima, Kenichi
    Iwasaki, Katsunori
    Fujiwara, Michihiro
    BEHAVIOURAL BRAIN RESEARCH, 2007, 178 (01) : 123 - 127
  • [24] Treatment of hyponatraemia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A/V2 receptor antagonist
    Abraham, W
    Koren, M
    Bichet, DG
    Verbalis, JG
    Klapholz, M
    Selaru, P
    Bakker-Arkema, RG
    Rummel, SA
    EUROPEAN HEART JOURNAL, 2000, 21 : 345 - 345
  • [25] Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure
    Udelson, JE
    Smith, WB
    Hendrix, GH
    Painchaud, CA
    Ghazzi, M
    Thomas, I
    Ghali, JK
    Selaru, P
    Chanoine, F
    Pressler, ML
    Konstam, MA
    CIRCULATION, 2001, 104 (20) : 2417 - 2423
  • [26] Effects of SRX246, a Vasopressin 1a Receptor (V1a) Antagonist, on an Experimental Model of Phasic and Sustained Threat in Humans
    Lago, Tiffany
    Brownstein, Michael
    Beydler, Emily
    Manbeck, Adrienne
    Beale, Alexis
    Simon, Neal
    Ernst, Monique
    Grillon, Christian
    BIOLOGICAL PSYCHIATRY, 2020, 87 (09) : S167 - S168
  • [27] Neuroprotective Effect of Aurantio-Obtusin, a Putative Vasopressin V1A Receptor Antagonist, on Transient Forebrain Ischemia Mice Model
    Paudel, Pradeep
    Kim, Dong Hyun
    Jeon, Jieun
    Park, Se Eun
    Seong, Su Hui
    Jung, Hyun Ah
    Choi, Jae Sue
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (07)
  • [28] Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice
    Isadora F Bielsky
    Shuang-Bao Hu
    Kathleen L Szegda
    Heiner Westphal
    Larry J Young
    Neuropsychopharmacology, 2004, 29 : 483 - 493
  • [29] BIOCHEMICAL AND PHARMACOLOGICAL PROPERTIES OF SR-49059, A NEW, POTENT, NONPEPTIDE ANTAGONIST OF RAT AND HUMAN VASOPRESSIN V1A RECEPTORS
    SERRADEILLEGAL, C
    WAGNON, J
    GARCIA, C
    LACOUR, C
    GUIRAUDOU, P
    CHRISTOPHE, B
    VILLANOVA, G
    NISATO, D
    MAFFRAND, JP
    LEFUR, G
    GUILLON, G
    CANTAU, B
    BARBERIS, C
    TRUEBA, M
    ALA, Y
    JARD, S
    JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (01): : 224 - 231
  • [30] Pharmacotherapy for hyponatraemia in heart failure: effects of a new combined vasopressin V1A/V2 receptor antagonist, conivaptan (YM087) administered orally
    Abraham, W
    Suresh, DP
    Wagoner, LE
    Haas, GJ
    Nelson, C
    Bakker-Arkema, RG
    EUROPEAN HEART JOURNAL, 2000, 21 : 345 - 345
12345